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Non-obstructive azoospermia (NOA), a severe form of male infertility, is often suspected to be linked to
currently undefined genetic abnormalities. To explore the genetic basis of this condition, we successfully
sequenced ,650 infertility-related genes in 757 NOA patients and 709 fertile males. We evaluated the
contributions of rare variants to the etiology of NOA by identifying individual genes showing nominal
associations and testing the genetic burden of a given biological process as a whole. We found a significant
excess of rare, non-silent variants in genes that are key epigenetic regulators of spermatogenesis, such as
BRWD1, DNMT1, DNMT3B, RNF17, UBR2, USP1 and USP26, in NOA patients (P 5 5.5 3 1027),
corresponding to a carrier frequency of 22.5% of patients and 13.7% of controls (P 5 1.4 3 1025). An
accumulation of low-frequency variants was also identified in additional epigenetic genes (BRDT and
MTHFR). Our study suggested the potential associations of genetic defects in genes that are epigenetic
regulators with spermatogenic failure in human.
A
zoospermia affects approximately 1% of all men and over 15% of infertile men1. Non-obstructive
azoospermia (NOA) is the most common form of azoospermia, and it is usually assumed to be caused
by genetic defects2. Although genetic aberrations such as karyotype abnormalities and Y chromosome
microdeletions have been identified in a small proportion of patients with NOA, the genetic causes for most
patients remain largely unknown3,4. Mouse studies have effectively identified the genes that are involved in the
reproductive processes, and hundreds of mouse mutants with spermatogenic defects have been produced in
the past decades4. Nevertheless, there has been little progress in translating of these results from animal
models into understanding the genetic causes of infertility in humans. Recently, SNP array-based association
studies in clinical patients identified several common tag SNPs with relatively modest effects on NOA
susceptibility5,6. However, reports on the identification of rare or low-frequency functional mutations in
specific genes with relatively larger effects are scarce. Thus, extensive analysis of both the common and
uncommon genetic variants for all genes implicated in the reproductive processes in large cohorts of infertile
patients, especially in those with the extreme phenotype of azoospermia, would be of great value to uncover
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To this end, 766 NOA patients without known karyotype abnor-
malities or Y chromosome microdeletions and 717 proven fertile
males from the same ethnic population were selected for analysis
of genetic defects in other candidate genomic regions. We isolated
DNA from the participants and sequenced the exonic regions of 654
genes, of which 299 have been reported to be associated with infer-
tility in humans and 355 are related to spermatogenic disorders in
knockout mice (SupplementaryMaterial, Table S1)4. A comprehens-
ive catalogue of genetic variants was generated in these candidate
genes and the potential contribution of both the common and rare
mutations to the predisposition of infertility inmale humanswas also
evaluated.
Results
Identification and validation of the genetic variants. After several
quality control steps (see Materials and method), 757 NOA patients
and 709 fertile males remained for further analysis (Supplementary
Material, Figure 1A and Table S2). A total of ,47.8 K genetic
variants, including 13.3 K non-silent variants and 8.2 K silent
coding variants, were identified in the combined population.
Across all the genes, over 90% of the genetic variants were variants
with minor allele frequencies (MAFs) less than 5% and over 85%
were rare variants with MAFs less than 1%. We then randomly
selected 75 novel variants (not reported as genetic polymorphisms
in the public database dbSNP137) for validation with Sanger
sequencing or Sequenom genotyping in 152 samples harboring
these variants (Supplementary Material, Table S3). 73 of the 75
tested sites were proved to be true positives, corresponding to a
false positive rate per site of 2.7%. Notably, novel variants in 147/
152 of the tested samples were successfully validated, corresponding
to a false positive rate for the SNV calls per individual of 3.3%.
Single-marker association tests for common and low-frequency
variants. To test whether there were any individual common (MAFs
$ 5%) or low-frequency variants (1% # MAFs , 5%) that would
show associations with NOA, we performed the logistic regression
analysis by including age as a covariate and applied a total of 10,000
permutations to determine the statistical significance. All the genetic
variants showing significant differences in their call rates or depths of
coverage between the patient and control groups were removed from
association analysis (P, 1025) to reduce the number of false positive
associations. We observed that no single common or low-frequency
variant remained significant after correcting for multiple tests
(Supplementary Material, Figure S2). There was also no obvious
trend of enrichment for common or low-frequency variants with
relatively small P values in the patient group (Supplementary
Material, Figure S3).
Gene-based analysis of rare and low-frequency variants. It has
been increasingly realized that the rare, higher-impact variants
may play a significant role in the etiology of a variety of human
diseases7–10. This may be especially true for the infertility related
disorders because genetic variants that are strongly associated with
infertility will scarcely be transmitted to offspring and will be less
likely to spread in the general population11. Since the gene or gene-set
based approaches usually provide improved power over the single
variant tests12, we first performed the gene-based association tests for
the rare variants (MAFs, 1%) alone and then with the rare variants
and low-frequency variants (1%#MAFs, 5%) together. The non-
silent variants and variants in the UTRs in each gene were combined
into two separate groups and the gene-based tests were performed for
them independently. The adaptive permutation model provided by
the PlinkSeq software was applied to obtain the empirical P values.
A total of 42 genes were identified to be nominally associated with
NOA by at least one of the four association tests, and nearly half (20/
42) of the genes were determined to show nominal associations by at
least two tests (permutated P , 0.05, Figure 1A). Also, none of the
nominally associated genes individually could pass the threshold of
multiple testing corrections (as 654 genes were sequenced). We then
focused on the promising candidate genes that were ranked top by
each gene-based analysis method in the list of candidate genes
(Table 1 and Supplementary Material, Table S4). Almost all of the
top ten genes identified by the BURDEN test showed significantly
higher carrier frequency in the NOA patients than in the controls
(Odds ratio (OR) 5 1.6524.25; P 5 0.0720.005). Five of the ten
genes had been proved to affect fertility in mice (Table 1).
Homozygous disruption of the transcription factor BRWD1, which
showed the most significant excess of rare non-silent variants in
NOA patients, results in a reduction in the counts of post meiotic
spermatocytes and epididymal sperm in male mice13. Impairment of
the LIMK2 gene leads to small testes size and partial degeneration of
spermatogenic cells in LIMK2-/- mice14.
We then analyzed whether there were any genes significantly
enriched with case-unique variants and identified 24 genes showing
an excess of rare, non-silent variants that were exclusive to NOA
patients by the UNIQ test (Supplementary Material, Figure S4).
For 75% (18/24) of these genes, at least 40% of the distinct variant
loci could only be observed in NOA patients. We then expanded the
control set to all those variants deposited in the public database
dbSNP137, which records genetic variants from thousands of indi-
viduals of unknown clinical statuses. For 75% (18/24) of the genes
showing enrichment for case-unique variants, over 60% of their case-
unique variants was also absent in dbSNP137 (Supplementary
Material, Figure S4). For example, four distinct missense variants
were identified in PTBP2, all of which were exclusive to NOA
patients and could not be found in dbSNP137. PTBP2 functions as
a RNA-binding protein and is involved in the regulation of exon
splicing and the stabilization of mRNA in mammalian testes15. Our
genetic evidence showed that rare, non-silent variants in PTBP2were
likely to be associated with NOA.
Excess of rare and low-frequency variants in genes that are
epigenetic regulator of spermatogenesis. Notably, of these top
genes and/or the genes showing an excess of case-unique variants,
many are involved in regulating the dramatic changes in epigenetic
profiles during spermatogenesis (Figure 2 and Supplementary
Material, Figure S5). BRWD1, a chromatin remodeling protein
with two bromodomains and multiple WD repeats, typically
interacts with chromatin regions containing the hyperacetylated
histones that are the characteristic marks of chromatin during
early spermatogenesis13. UBR2, a RING finger E3 ubiquitin ligase,
associates with meiotic chromatin regions and silences gene
expression by ubiquitinating histone H2A16. RNF17, another
RING finger protein, has been proved to be a key regulator of
spermiogenesis and RNF17-/- male mice are infertile due to a
complete arrest of spermatogenesis in the round spermatid stage17.
USP26 is an ubiquitin-specific protease that cleaves the ubiquitin
moiety from the ubiquitinylated proteins18. DNMT1 is an impor-
tant DNA methylation enzyme capable of maintaining the estab-
lished DNA methylation patterns, while DNMT3B is considered to
be responsible for the establishment of de novo methylation19,20.
NSUN3 is inferred to be a putative methyltransferase by sequence
comparison analysis, and further studies are needed to confirm its in
vivo functions.
When the gene-based analyses were further performed with
non-silent variants with MAFs less than 5% (including both the
low-frequency and rare variants), the association signals for the epi-
genetic genes mentioned above could be consistently detected. In
addition, two other epigenetic genes also showed an excess of rare
and low-frequency non-silent variants in the patients (Figure 1B).
BRDT encodes another bromodomain containing protein which
binds histiones with acetylated lysines and is implicated in chromatin
www.nature.com/scientificreports
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remodeling. Previous studies demonstrated that male mice with
defective BRDT produced fewer sperm and were sterile21. MTHFR
encodes an essential enzyme for maintaining the bioavailability of
methionine, which can be converted to the methyl donor, S-adeno-
sylmethionine, for a number of biological processes such as the
methylation of DNA and histones22.
Pathway analysis of the nominally associated genes. The above
findings suggested that some biological processes or pathways were
likely to be enriched with genes that individually only nominally
associated with NOA. To assess whether there was an enrichment
of the nominally associated genes in any groups of genes or pathways,
literature and database searches were used to compile several groups
of genes or pathways from our list of candidate genes (Table 2). The
large group of epigenetic genes was generally defined as those
genes that are involved in biological processes relevant to histone
modifications, chromatin remodeling and DNA methylation.
The other groups of genes or pathways potentially relevant to the
pathophysiology of NOAwere defined by searching the related terms
in the KEGG and PANTHER pathway databases. Hypergeome-
tric tests were applied to determine the statistical significance of
enrichment of the nominally associated genes in each pathway or
group of genes. Our analysis indicated that the group of genes
regulating the dynamic epigenetic changes during spermatogenesis
was significantly enriched with multiple nominally associated genes
(P 5 0.002).
Figure 1 | The nominally associated genes identified by four different gene-based tests. (A) Nominally associated gens identified by evaluation of
rare non-silent variants in each gene. (B) Nominally associated genes identified by evaluation of both rare and low-frequency non-silent variants in each
gene. (C) Nominally associated genes identified by evaluation of rare variants in the UTRs of each gene. (D) Nominally associated genes identified by
evaluation of both rare and low-frequency variants in the UTRs of each gene. The height of each bar is proportional to the –log10 P value from the
respective gene based test and P values$0.05 are not shown in the plots. # indicates the gene was determined to be nominally associated with NOA by at
least two different tests.
www.nature.com/scientificreports
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The genetic burden of rare and low-frequency variants in the
epigenetic genes. To further test the overall genetic burden of rare
and low-frequency variants of these epigenetic genes in the NOA
patients, all of the non-silent variants in the epigenetic genes that
showed nominal associations with NOA were aggregated and the
significance of accumulation of rare and low-frequency variants in
the epigenetic genes as a whole was tested (Table 3). In total, 1.8 times
more distinct rare variant loci in the NOA patients were detected
than in the controls. We detected 197 rare variants in the NOA
patients versus 105 in the normal controls (OR 5 1.9; P 5 5.5 3
1027), corresponding to a carrier frequency of 22.5% in patients with
NOA compared to 13.7% in the controls (P 51.43 1025). Of those
variants exclusive to either the NOA patients or controls, 126 rare
variants were case-unique variants while 49 were control-unique
variants (OR 5 2.5; P 5 2.0 3 1028). In our analysis of the rare
and low-frequency variants together, the same trend of a
significant excess of non-silent variants in the epigenetic genes
were also noticed in the NOA patients (Table 3).
Discussion
Previous association studies on NOA had been mainly focused on
common genetic variants. In the present study, both common and
uncommon (rare or low-frequency) genetic variants in ,650 genes
related to the reproduction processes were analyzed for their asso-
ciation withNOA in a relatively large cohort of patients and controls.
It’s often interesting to investigate whether there are any genetic
regions where both common and rare variants are associated with
the disease phenotypes. In our study, no gene showed obvious trend
of enrichment for the nominally associated common SNPs and rare
(or low-frequency) non-silent variants (Supplementary Material,
Figure S2). However, because only the coding sequences and flanking
regions of the candidate genes were sequenced, it remains to be
determined whether there is an enrichment of the common dis-
ease-associated intronic or intergenic SNPs relatively far from those
genes showing an excess of rare non-silent variants.
Although a large number of the candidate genes investigated in the
current study have been shown to cause male infertility in animal
models4, our data demonstrated that most of the non-silent variants
in these genes in the sporadic NOA patients were heterozygous mis-
sense mutations which could only be found in a few individuals, and
few of the rare variants were truncating mutations resulting in loss of
gene functions. Moreover, none of the candidate genes individually
showed association signals that were significant enough to survive
the multiple testing corrections. These findings suggested that the
genetic causes for the majority of the sporadic NOA patients were
quite complex. The gene-set or pathway-based association tests
which can aggregate genetic evidence from multiple functionally
related genes appear to be more appropriate and powerful for detect-
ing the genetic associations. On the other hand, each pathway or
gene-set consists of tens to hundreds of genes, and only some of them
are associated with the disease. Therefore, the gene-based analyses
may serve as the cornerstones of the gene-set or pathway based
analyses. In this way, we evaluated the overall genetic burdens of
several groups of genes and pathways. Our results showed that rare
or low-frequency variants in genes that are key epigenetic regulators
of spermatogenesis were significantly associated with NOA
(Table 3), which provided new clues about the genetic causes of
the epigenetic aberrations that occurred frequently in male patients
with infertility or sub-fertility.
In fact, male germ cells show epigenetic profiles that are highly
distinct from those of somatic cells and oocytes. During spermato-
genesis, the epigenetic profiles of sperm genomes undergo extensive
DNA demethylation, followed by DNA methylation and chromatin
remodeling23,24. In maturing sperm cells, there is an additional pro-
cess of chromatin remodeling, called the histone-to-protamine
transition, which replaces most histones with protamines to compact
chromatin23. Therefore, it is quite plausible that genetic defects in
genes that are key epigenetic regulators (as caused by the rare or low-
frequency variants) could lead to abnormal spermatogenesis25. There
is enormous evidence in previous studies demonstrating that sperm
samples from patients with oligozoospermia or oligoasthenoterato-
zoospermia often contain altered epigenetic modifications26,27. Our
findings raised the possibility that genetic defects in genes that are the
key epigenetic regulators of spermatogenesis were likely to contrib-
ute to these aberrant epigenetic profiles.
Methods
Sample preparation. Peripheral blood samples from all of the NOA patients and
normal controls were collected from the Peking University Shenzhen Hospital and
Table 1 | The top genes that showed an excess of rare, non-silent variants in the NOA patients
Gene BURDEN FRQWGT UNIQ VT
Carrier frequency (%)
OR Fisher PCases Controls
BRWD1a 7.43 1024 9.93 1024 2.73 1023 1.53 1023 7.27 4.09 1.84 0.01
PDGFC 3.63 1023 1.63 1023 -- 3.83 1023 2.51 0.71 3.62 0.007
ATF4 4.13 1023 9.13 1023 -- 7.93 1023 2.64 0.85 3.18 0.01
LIMK2a 6.73 1023 8.13 1023 4.13 1022 9.53 1023 3.43 1.13 3.11 0.005
ADORA1a 7.53 1023 7.03 1023 1.53 1022 2.23 1022 1.72 0.42 4.11 0.02
CDA 1.33 1022 2.63 1022 9.43 1023 2.63 1022 1.85 0.56 3.32 0.03
TSSK2a 1.43 1022 1.43 1022 1.53 1022 2.03 1022 2.38 0.85 2.85 0.02
UBR2a 1.93 1022 3.03 1022 -- -- 5.68 3.39 1.97 0.04
USP26 2.03 1022 3.23 1022 1.53 1022 2.03 1022 1.19 0.28 4.25 0.07
TCEB3B 2.13 1022 5.43 1023 -- 3.43 1022 7.00 4.37 1.65 0.03
RAD23Ba 2.63 1022 2.33 1022 -- -- 1.19 0.28 4.25 0.07
SOX9 2.83 1022 1.93 1022 -- 3.13 1022 1.32 0.42 3.15 0.09
SLC19A2a 3.33 1022 2.63 1022 1.93 1022 4.73 1022 1.32 0.42 3.15 0.09
VDRa 4.53 1022 2.13 1022 2.93 1022 1.13 1022 1.45 0.56 2.60 0.12
SLC19A1a -- -- 1.63 1022 -- 1.85 0.99 1.89 0.19
CDKN1Ba -- -- 4.93 1023 -- 1.32 0.56 2.36 0.18
ETV5a -- -- 2.33 1022 -- 0.66 0.14 4.70 0.22
RNF17a -- 4.53 1022 1.43 1022 2.23 1022 3.70 2.54 1.47 0.23
DNMT3B -- -- 2.53 1022 -- 3.96 2.82 1.42 0.25
SULT1E1a -- -- -- 2.03 1022 1.19 0.56 2.12 0.27
DNMT1 -- 3.93 1022 -- 1.33 1022 1.72 0.99 1.75 0.27
agenes proven to cause infertility in mouse mutants when deleted. Genes shown in bold are epigenetic regulators of spermatogenesis.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8785 | DOI: 10.1038/srep08785 4
the Center of Reproductive Medicine, Tongji Medical College, Huazhong University
of Science and Technology. The inclusion criteria for the NOA patients included the
following: (i) no sperm detected in the pellets of semen samples on three different
occasions; (ii) no inflammation or injury of the reproductive system or pelvic cavity;
and (iii) no karyotypic abnormality or Y chromosomemicrodeletion. Y chromosome
microdeletions were detected as described previously28. Testicular biopsy and
Figure 2 | Rare non-silent variants identified in genes that are key epigenetic regulators of spermatogenesis. Variants shown above the indicated
genemaps were detected in NOApatients, and variants shown below the indicated genemaps were detected in controls. Rare variants that were identified
in both the patient and control groups are colored black, and rare variants that were exclusive to the NOA patients and normal controls are colored blue
and pink, respectively. Boxes labeled in red represent the UTRs and boxes labeled in black represent the exons.
Table 2 | Nominally associated genes detected in different groups of genes or pathways
Pathways or groups of genes* # of genes sequenced # of genes showing excessive of non-silent variants P FDR
Epigenetic genes 50 10 2.03 1023 2.43 1022
PI3 kinase pathway 11 3 1.03 1022 6.03 1022
GnRH signaling pathway 16 2 0.17 0.63
MAPK signaling pathway 26 3 0.26 0.63
Steroid hormone biosynthesis and metabolism 12 1 0.30 0.63
DNA repair or recombination 14 1 0.37 0.63
Cell cycle 14 1 0.37 0.63
Meiosis 19 1 0.53 0.73
Apoptosis 21 1 0.58 0.73
TGF signaling pathway 22 1 0.61 0.73
P53 signaling pathway 20 0 0.86 0.87
Wnt signaling pathway 21 0 0.87 0.87
*only those pathways or groups of genes that had more than 10 component genes sequenced were analyzed and shown.
www.nature.com/scientificreports
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histological analysis were conducted for the azoospermic men whenever possible. All
of the control men had fathered at least one child without assisted reproductive
techniques such as IVF, ICSI or IMSI. This study was approved by the ethical
committees of PekingUniversity ShenzhenHospital and Tongji Medical College, and
all participants signed a consent form permitting the collection and use of their blood
samples in the study. The methods used in this study were carried out in accordance
with the approved guidelines.
Targeted sequencing. Genomic DNA was extracted and randomly fragmented by
sonication to an average size of 250 bp. The resulting fragments were end repaired
and A-tailed, then ligated to a pair of adaptors. The adaptor-ligated DNA products
were amplified using index tagged primers in order to tag DNA from different
individuals. The amplified products were purified with QIAquick PCR purification
kits (QIAGEN) and hybridized to the custom-designed capture array as per
NimbleGen’s Sequence Capture protocol for enrichment. Each enriched library was
loaded on the HiSeq 2000 platform and pair-end reads with the lengths of 90 bp were
generated. The raw image files were processed by the Illumina Genome Analyzer
Pipeline (v1.7) for base-calling with default parameters.
Identification of genetic variants. Genetic variants that differ from the reference
genome sequence were extracted as follows: (i) GLFv3 files that contain the genotype
likelihoods of ten possible genotypes at each nucleotide site were generated for all
individuals using SAM tools (v.0.1.16); (ii) the maximum likelihood estimate of
population allele frequency was calculated from the genotype likelihoods using the
expectation-maximization (EM) algorithm, and a SNP was called if two times the log
likelihood ratio of the SNP model against the null model for a given genomic site was
greater than 24 (likelihood ratio test); (iii) for each variant site, Bayesian-based
genotype calling was performed for each individual by using the ML estimate of
population allele frequency as a prior; and (iv) LD-based genotype calling was
performed with BEAGLE using the candidate genetic variants and genotype
likelihoods as input29.
Several filtering steps were then applied to reduce the false positives in variant
calling. Candidate variant loci that met any one of the following criteria were filtered
out: (i) base quality scores of the minor alleles significantly smaller than those of the
major alleles (P, 1025) when we performed rank sum tests across all individuals; (ii)
loci showing significant strand biases for either the major or minor alleles across all
individuals (P , 1025); and (iii) loci with extremely high or low depths or of low
mapping qualities. Moreover, those candidate variants with coverage less than 83
were also removed for each individual.
Validation of genetic variants.Novel variants were randomly selected for validation
with Sanger sequencing or Sequenom genotyping.
Statistical analysis. To identify the common or low-frequency variants that are likely
associated with NOA, the logistic regression analysis followed by permutation test
were used to determine the statistical significance. Several complementary gene-
based association tests included in the PlinkSeq software package were used to
identify the candidate genes that are likely enriched with multiple functional
mutations in the NOA patients. The BURDEN test compares the excess of minor
alleles between patients and normal controls, while the FRQWGT test takes MAFs in
controls as a weight function when comparing the excess of minor alleles. The VT test
gives more weight to very rare variants, while the UNIQ test gives more weight to
case-unique variants. The adaptive permutation model provided by the PlinkSeq
software was applied to obtain the empirical P values. The hypergeometric test was
applied to determine the statistical significance of enrichment of the nominally
associated genes in each pathway or group of genes.
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